Labor ComplicationPhase 2GELFREQNCT04413890
Comparison of Two Rhythm of Administration of Prostaglandin Gel for Induction of Labor
A Phase 2 study testing Dinoprostone vaginal gel in people with Labor Complication and Cervix, run by University Hospital Center of Martinique at 1 site in Martinique.
Trial summary
The study compares two rhythms of administration of prostaglandin vaginal gels for cervical priming before induction of labor in term patients. In our institution, prostaglandin gels are given for a maximum of three times, with induction by oxytocin and amniotomy the day after the last gel whatever Bishop score has… Read more about this study
- Who is it for?
- Ages 18 to 49 years, women only
- Conditions the study is for
- Labor Complication, Cervix
- What is being tested?
- Dinoprostone vaginal gel
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 268 participants
- Where
- 1 siteMartinique
- Study dates
- 17 Dec 2019to 27 Jan 2021
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 49 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Patients above 18 years
- Gestational age ≥ 37 weeks
- With indicated induction of labor and initial Bishop score under 6
- Without any contraindication to vaginal delivery
- Who consent to participate to the clinical research
- With French Medical Public Insurance
Who cannot join
- Multiple pregnancy
- Previous uterine scar (for myomas or cesarean section)
- Fetus not in cephalic presentation
- Allergy to prostaglandins
- Who not consent to participate to the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Administration of Prostaglandin Gel for Cervical Priming During Induction of Labour Every 12 Hours Versus 24 Hours: a Randomized Superiority Controlled Trial
The study compares two rhythms of administration of prostaglandin vaginal gels for cervical priming before induction of labor in term patients. In our institution, prostaglandin gels are given for a maximum of three times, with induction by oxytocin and amniotomy the day after the last gel whatever Bishop score has been obtained. This management results in some patient spending four days in hospital before delivery. The aim of the study is to compare our classical management scheme with a reduced interval between to gels, of 12h instead of 24 h. The primary outcome will be the time elapsed between the first prostaglandin gel and delivery. Tolerance of both management patterns will also be evaluated through a satisfaction survey.
Read the detailed description
Approximatively 22% of pregnant women have an induction of labor in France (22.9% in our institution in 2019), mainly for prolonged pregnancy after 41 weeks gestational age or prolonged rupture of membranes. Patients whose cervix is considered unripe (Bishop score under 6) are generally proposed a cervical priming because induction of labor without prior priming entails a higher of cesarean delivery rate for failed induction. The devices used for cervical priming are pharmacological (mainly prostaglandin gel, pessaries or suppositories) or mechanical (Foley catheter, Cook balloons). Very few recommendations exist regarding the type of device, the rhythm and maximal number of repeat administrations and the interval between two administrations. Shortening interval between two administrations (in case of use of a device necessitating serial prescriptions) may shorten the time interval between beginning of priming and delivery. In our institution, a vaginal gel can be given three times before induction of labor with oxytocin and amniotomy, whatever Bishop score has been obtained after priming. These gels are given on a daily basis. This rhythm implies than for some women not responding to a first gel, priming can last up to three days, lengthening hospital stay and leading to maternal weariness. Maternal satisfaction during induction of labor is seldom analyzed. An intensification in gel administration implies a change in maternal management during the induction process, with shortened periods of rest between two gels and nearer periods of pain and discomfort, albeit on a theoretically shorter period. The way patients deal with this new rhythm compared to the classical in part of the evaluation in this study. All patients having a singleton pregnancy and an indication for term (≥ 37 weeks gestation age) induction with an unfavorable cervix and no contraindication to vaginal delivery will be eligible. Patients with fetuses in breech presentation, a scarred uterus, under 18 years, bearing a fetus with antenatally known malformation, not fluent in French or presenting an allergy to prostaglandins will be excluded. A written informed consent will be required before inclusion. The primary outcome will be the duration between first priming with prostaglandin gel and delivery. Secondary outcomes will be the satisfaction of patients with their induction process (measured through a survey answered during the in-hospital post-partum stay), the rate of cesarean section, the rate of hypertonia/hypercinesia during priming and induction requiring medical intervention, the length of active phase of labor (after 5 cm of dilation), the oxytocin doses used during delivery for induction or augmentation, initial neonatal (Apgar score, arterial cord pH and lactates, resuscitation maneuvers, transfer to intensive care unit) and maternal (post-partum hemorrhage, hyperthermia during labor, perineal laceration > 2nd degree and endometritis) morbidity and length of total hospital stay. The investigators calculated that a sample of 268 patients (134 in each group) will be necessary to detect a 30% reduction in duration between first priming and delivery in the experimental group (one gel every 12h) compared with the classical group. Mean time frame between first priming and delivery has been measured in our department in 2018 to 31.8 hours (standard deviation 27.6 hours).
- Conditions
- Labor Complication, Cervix
- Being tested
- Dinoprostone vaginal gel
- Keywords
- Induction, Term, Labor, Rhythm, Prostaglandins
- Medical subject headings
- Obstetric Labor Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dinoprostone vaginal gelDrug
Also called cervical priming with prostaglandin gel
Prostaglandin gel 0.5, 1 or 2 mg
| Study group | Role | What they receive |
|---|---|---|
| Classical administration | Active comparator | One prostaglandin vaginal gel every 24 hours Receives: Drug: Dinoprostone vaginal gel |
| Experimental administration | Experimental | One prostaglandin vaginal gel every 12 hours Receives: Drug: Dinoprostone vaginal gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time between gel administration and delivery
Time between first gel administration for cervical priming and delivery
Measured: At inclusion (Day 0)
Time between gel administration and delivery
Change between cervical priming and delivery
Measured: At 12 hours or 24 hours (after each gel administration)
Time between gel administration and delivery
Time between first gel administration for cervical priming and delivery
Measured: Time 0 after the childbirth
Time between gel administration and delivery
Time between first gel administration for cervical priming and delivery
Measured: Until 5 days postpartum (during in-hospital postpartum period)
Secondary outcomes (12)
Maternal satisfaction
maternal satisfaction measured by survey self-administered during postpartum hospital stay
Measured: Until 5 days postpartum
Cesarean section rate
Measured: During labor
Hypertonia / hypercinesia rate
Hypertonia (rise of uterus tone more than 10 minutes)/hypercinesia (more than 5 uterine contractions per 10 minutes) rate during priming and induction
Measured: During priming and induction
Oxytocin dose during labor
Induction or augmentation of Oxytocin doses
Measured: During labor
Length of active first phase of labor
Induction or augmentation of active first phase of labor
Measured: During labor
Maternal morbidity
Fever during labor, perineal laceration superior to 2nd degree, postpartum hemorrhage, endometritis
Measured: During labor
Neonatal immediate morbidity
Assess if Apgar score is less than 7
Measured: 5 minutes after childbirth
Neonatal immediate morbidity
Assess of arterial cord pH level
Measured: 5 minutes after childbirth
Neonatal immediate morbidity
Assess of arterial cord lactate level
Measured: 5 minutes after childbirth
Neonatal immediate morbidity
Concentration of arterial cord lactates level (in Mmol/L)
Measured: 5 minutes after childbirth
Neonatal immediate morbidity
Occurence or not of resuscitation maneuvers in delivery room
Measured: 5 minutes after childbirth
Neonatal immediate morbidity
Occurence or no transfer of the child to neonatal intensive care unit
Measured: 5 minutes after childbirth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2020
- Study start17 Dec 2019
- Primary completion27 Jan 2021
- Study completion27 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Labor ComplicationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 268 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Center of Martinique
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jean-Luc VOLUMENIE, Principal investigator, University Hospital of Martinique
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04413890
- Sponsor's protocol ID
- 19_RIPH2_10
- Acronym
- GELFREQ
- Status last verified
- Jul 2023
- First submitted
- 7 Apr 2020
- Last updated
- 19 Jul 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Administration of Prostaglandin Gel for Cervical Priming During Induction of Labour Every 12 Hours Versus 24 Hours: a Randomized Superiority Controlled Trial
- ClinicalTrials.gov ID
- NCT04413890
- Acronym / sponsor ID
- GELFREQ / 19_RIPH2_10
- Conditions
- Labor Complication, Cervix
- Keywords
- Induction, Term, Labor, Rhythm, Prostaglandins
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 268 participants (actual)
- Lead sponsor
- University Hospital Center of MartiniqueUniversity, hospital or other
- Study start
- 17 Dec 2019 (actual)
- Primary completion
- 27 Jan 2021 (actual)
- Study completion
- 27 Jan 2021 (actual)
- First posted
- 4 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study compares two rhythms of administration of prostaglandin vaginal gels for cervical priming before induction of labor in term patients. In our institution, prostaglandin gels are given for a maximum of three times, with induction by oxytocin and amniotomy the day after the last gel whatever Bishop score has been obtained. This management results in some patient spending four days in hospital before delivery. The aim of the study is to compare our classical management scheme with a reduced interval between to gels, of 12h instead of 24 h. The primary outcome will be the time elapsed between the first prostaglandin gel and delivery. Tolerance of both management patterns will also be evaluated through a satisfaction survey.
Detailed description
Approximatively 22% of pregnant women have an induction of labor in France (22.9% in our institution in 2019), mainly for prolonged pregnancy after 41 weeks gestational age or prolonged rupture of membranes. Patients whose cervix is considered unripe (Bishop score under 6) are generally proposed a cervical priming because induction of labor without prior priming entails a higher of cesarean delivery rate for failed induction. The devices used for cervical priming are pharmacological (mainly prostaglandin gel, pessaries or suppositories) or mechanical (Foley catheter, Cook balloons). Very few recommendations exist regarding the type of device, the rhythm and maximal number of repeat administrations and the interval between two administrations. Shortening interval between two administrations (in case of use of a device necessitating serial prescriptions) may shorten the time interval between beginning of priming and delivery. In our institution, a vaginal gel can be given three times before induction of labor with oxytocin and amniotomy, whatever Bishop score has been obtained after priming. These gels are given on a daily basis. This rhythm implies than for some women not responding to a first gel, priming can last up to three days, lengthening hospital stay and leading to maternal weariness. Maternal satisfaction during induction of labor is seldom analyzed. An intensification in gel administration implies a change in maternal management during the induction process, with shortened periods of rest between two gels and nearer periods of pain and discomfort, albeit on a theoretically shorter period. The way patients deal with this new rhythm compared to the classical in part of the evaluation in this study. All patients having a singleton pregnancy and an indication for term (≥ 37 weeks gestation age) induction with an unfavorable cervix and no contraindication to vaginal delivery will be eligible. Patients with fetuses in breech presentation, a scarred uterus, under 18 years, bearing a fetus with antenatally known malformation, not fluent in French or presenting an allergy to prostaglandins will be excluded. A written informed consent will be required before inclusion. The primary outcome will be the duration between first priming with prostaglandin gel and delivery. Secondary outcomes will be the satisfaction of patients with their induction process (measured through a survey answered during the in-hospital post-partum stay), the rate of cesarean section, the rate of hypertonia/hypercinesia during priming and induction requiring medical intervention, the length of active phase of labor (after 5 cm of dilation), the oxytocin doses used during delivery for induction or augmentation, initial neonatal (Apgar score, arterial cord pH and lactates, resuscitation maneuvers, transfer to intensive care unit) and maternal (post-partum hemorrhage, hyperthermia during labor, perineal laceration > 2nd degree and endometritis) morbidity and length of total hospital stay. The investigators calculated that a sample of 268 patients (134 in each group) will be necessary to detect a 30% reduction in duration between first priming and delivery in the experimental group (one gel every 12h) compared with the classical group. Mean time frame between first priming and delivery has been measured in our department in 2018 to 31.8 hours (standard deviation 27.6 hours).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Classical administration | Active comparator | Drug: Dinoprostone vaginal gelOne prostaglandin vaginal gel every 24 hours |
| Experimental administration | Experimental | Drug: Dinoprostone vaginal gelOne prostaglandin vaginal gel every 12 hours |
Who may qualify
- Ages
- 18 to 49 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Patients above 18 years
- Gestational age ≥ 37 weeks
- With indicated induction of labor and initial Bishop score under 6
- Without any contraindication to vaginal delivery
- Who consent to participate to the clinical research
Key exclusion criteria (5 listed)
- Multiple pregnancy
- Previous uterine scar (for myomas or cesarean section)
- Fetus not in cephalic presentation
- Allergy to prostaglandins
- Who not consent to participate to the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dinoprostone vaginal gelAlso: cervical priming with prostaglandin gelProstaglandin gel 0.5, 1 or 2 mg | Drug | Classical administration, Experimental administration |
Primary outcome
Time between gel administration and delivery
Time frame: At inclusion (Day 0)
Time between first gel administration for cervical priming and delivery
Time between gel administration and delivery
Time frame: At 12 hours or 24 hours (after each gel administration)
Change between cervical priming and delivery
Time between gel administration and delivery
Time frame: Time 0 after the childbirth
Time between first gel administration for cervical priming and delivery
Time between gel administration and delivery
Time frame: Until 5 days postpartum (during in-hospital postpartum period)
Time between first gel administration for cervical priming and delivery
12 secondary outcomes
Maternal satisfaction
Time frame: Until 5 days postpartum
Cesarean section rate
Time frame: During labor
Hypertonia / hypercinesia rate
Time frame: During priming and induction
Oxytocin dose during labor
Time frame: During labor
Length of active first phase of labor
Time frame: During labor
Maternal morbidity
Time frame: During labor
Neonatal immediate morbidity
Time frame: 5 minutes after childbirth
Neonatal immediate morbidity
Time frame: 5 minutes after childbirth
Neonatal immediate morbidity
Time frame: 5 minutes after childbirth
Neonatal immediate morbidity
Time frame: 5 minutes after childbirth
Neonatal immediate morbidity
Time frame: 5 minutes after childbirth
Neonatal immediate morbidity
Time frame: 5 minutes after childbirth
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jul 2023.
Related trials for Labor Complication
Not yet recruiting
nCPAP-NAVA-Backup Versus Standard nCPAP for Severe Apnea in Preterm Infants ≤28 Weeks
Apnea of Prematurity
Not yet recruiting
Comparison of Effect of Two Different Doses of Intravenous Oxytocin on Patients Undergoing Elective Cesarean Section
Postpartum Hemorrhage, Uterine Atony
Recruiting
Study of the Influence of Intraperitoneal Insufflation of CO2 by Laparoscopy on the Short-term Evolution of Premature Infants With Ulcerative Necrotizing Enterocolitis
Preterm Birth, Enterocolitis, Necrotizing
RecruitingObservational study
Multidimensional Dynamic Early Warning System for Neonatal Necrotizing Enterocolitis: A Multicenter Clinical Study
NEC - Necrotizing Enterocolitis
RecruitingObservational study
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jean-Luc VOLUMENIE principal investigator
University Hospital of Martinique
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Dinoprostone vaginal gel in people with Labor Complication and Cervix, run by University Hospital Center of Martinique at 1 site in Martinique.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Martinique. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time between gel administration and delivery (time frame: At inclusion (Day 0)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2023.